Adocia SA, a clinical-stage biotechnology company headquartered in Lyon, France, continues to make significant strides in the health care sector, particularly within the biotechnology industry. The company is dedicated to researching and developing innovative formulations of pre-approved therapeutic proteins and peptides aimed at treating diabetes and other metabolic diseases. Adocia’s proprietary BioChaperone technological platform is at the forefront of this endeavor, utilizing novel polymers, oligomers, and small molecules to enhance the efficacy and safety of therapeutic proteins.
As of December 4, 2025, Adocia’s stock closed at 7.54 EUR on the NYSE Euronext Paris, where it is publicly traded. The company’s market capitalization stands at 137,660,000 EUR. Despite a challenging financial landscape, reflected in a price-to-earnings ratio of -13.41, Adocia’s commitment to innovation remains unwavering. The company’s stock has experienced significant volatility over the past year, reaching a 52-week high of 12.4 EUR on October 14, 2025, and a low of 2.86 EUR on April 6, 2025.
Adocia’s clinical product pipeline is robust, featuring a range of insulin formulations designed to improve diabetes management. Key products include BioChaperone Lispro U100 and U200, ultra-rapid formulations of insulin analogs, and HinsBet U100, a rapid-acting formulation of human insulin. Additionally, the company is developing BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro, and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide. BioChaperone Human Glucagon, an aqueous formulation of human glucagon, is also part of their innovative offerings.
Beyond diabetes, Adocia is expanding its focus to address other metabolic conditions. The company is developing BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide, which combine insulin glargine with GLP-1s. BioChaperone Teduglutide, an aqueous formulation of teduglutide, a GLP-2 analog, is being developed for the treatment of short bowel syndrome. Additionally, BioChaperone Glucagon GLP-1, a combination of glucagon and a GLP-1 receptor agonist, is being explored for obesity treatment.
Adocia’s strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. underscores its commitment to expanding its reach and impact in the global market. Founded in 2005, Adocia continues to leverage its innovative BioChaperone platform to address unmet medical needs in the treatment of metabolic diseases. For more information, Adocia’s official website is www.adocia.com .
